Cost-effectiveness of BTK inhibitors vs bendamustine and rituximab in chronic lymphocytic leukemia patients.

Nie, Jing; Wu, Huina; Wu, Qian; Liu, Qi; Liu, Lihui; Wu, Jiyong

Nie, Jing; Wu, Huina; Wu, Qian; Liu, Qi; Liu, Lihui; Wu, Jiyong.

Afiliação

Nie J; Department of Pharmacy, Shandong Second Provincial General Hospital, Jinan, Shandong, China.
Wu H; Department of Pharmacy, Shandong Second Provincial General Hospital, Jinan, Shandong, China.
Wu Q; Department of Pharmacy, Shandong Second Provincial General Hospital, Jinan, Shandong, China.
Liu Q; Department of Pharmacy, Shandong Second Provincial General Hospital, Jinan, Shandong, China.
Liu L; Department of Pharmacy, Shandong Second Provincial General Hospital, Jinan, Shandong, China.
Wu J; Department of Pharmacy, Shandong Second Provincial General Hospital, Jinan, Shandong, China.

Future Oncol ; 19(38): 2525-2536, 2023 Dec.

Article em En | MEDLINE | ID: mdl-38059348

Assuntos

Leucemia Linfocítica Crônica de Células B; Humanos; Rituximab/uso terapêutico; Cloridrato de Bendamustina/uso terapêutico; Leucemia Linfocítica Crônica de Células B/tratamento farmacológico; Leucemia Linfocítica Crônica de Células B/etiologia; Análise Custo-Benefício; China; Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos

Palavras-chave

bendamustine-rituximab; bruton tyrosine kinase; chronic lymphocytic leukemia; costeffectiveness; ibrutinib; zanubrutinib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Humans País/Região como assunto: Asia Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google